Trial Profile

Phase IB Study of FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PF 4136309 (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
Indications Pancreatic cancer
Focus Adverse reactions

Most Recent Events

15 Sep 2016 Status changed from active, no longer recruiting to completed.
04 Apr 2016 Results published in the Lancet Oncology
22 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com